Pernix Therapeutics Holdings (PTX) Posts Q2 GAAP Loss of 16c/Share

Pernix Therapeutics Holdings (NASDAQ: PTX) reported Q2 EPS of ($0.16), $0.11 worse than the analyst estimate of ($0.05). Revenue for the quarter came in at $17.4 million versus the consensus estimate of $26.2 million.

For earnings history and earnings-related data on Pernix Therapeutics Holdings (PTX) click here.

You May Also Be Interested In

• JPMorgan is worried about further S&P 500 sell-off potential
• HSBC Starts Auna SA (AUNA) at Buy, 'Just what the doctor prescribed'
• LKQ Corporation (LKQ) Misses Q1 EPS by 13c, provides guidance